Femasys vs Insight Molecular Diagnostics
Insight Molecular Diagnostics is the larger business, with $4.1m of revenue in fiscal 2025 against $2.3m for Femasys (1.8 times as much). Insight Molecular Diagnostics grew faster (115.6% against 40.8%). Femasys kept more of each dollar of sales as profit: a net margin of -812.3% against -1238.5%.
| Latest fiscal year | FemasysFEMY, 2025 | Insight Molecular DiagnosticsIMDX, 2025 |
|---|---|---|
| Revenue | $2.3m | $4.1m |
| Revenue growth | 40.8% | 115.6% |
| Net income | −$18.6m | −$50.2m |
| Operating margin | -767.0% | — |
| Net margin | -812.3% | -1238.5% |
| Return on equity | — | — |
| Free cash flow | −$19.2m | −$25.4m |
| Cash | $9.3m | $11.6m |
| Total debt | $3.2m | $0 |
| Debt to equity | 54.2% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 51 | — |
| Market value | $4.1m | $91.3m |
| Price vs our value range | — | — |
| Moat score | 37 (Weak) | 20 (Weak) |
| Insider trades, 12 months | 5 buys, 0 sales | 14 buys, 0 sales |